MPJE RHODE ISLAND STUDY GUIDE
QUESTIONS WITH CORRECT
ANSWERS
HowIlongIshouldIRXIbeIkeptI-ICORRECTIANSWERS-5IyearsIFDA,I10IyearsIMMA
importIinformationIprescriptionIlabelI-ICORRECTIANSWERS-
ptIname,IrxIserialInumber,IdrugIname,Istrength,IandIdirections
AIproductIisI________IifIitIdoesInotIhaveIanIexpirationIdateI-ICORRECTIANSWERS-misbranded
WhoIcanIprovideIaIblanketIwaiverIforInon-childIresistantIcontainerI-ICORRECTIANSWERS-
patientI(physicianIcanIonlyIdoIitIbyIRX)
WhenIareIchildIresistantIcontainersInotIusedI-ICORRECTIANSWERS-hospital/healthcareIsettings
AIpharmacyIdispensingItoIaILTCFIrequiresIwhatItypeIofIcontainerI-ICORRECTIANSWERS-
childIresistant
PolicyIforIreversibleIclosuresI-ICORRECTIANSWERS-discouragedIbyICPSC
productsIexemptIfromIchildIclosuresI-ICORRECTIANSWERS-
sublingualInitro,Isublingual/chewableIisosorbideIdinitrate,Imethylprednisone,Ibetamethasone,
PharmaceuticallyIequivalentI-ICORRECTIANSWERS-
sameIingredient,IdosageIform,Iroute,Istrength/concentration
therapeuticallyIequivalentI-ICORRECTIANSWERS-pharmaIequivIandIbioequivalent
, bioequivalentI-ICORRECTIANSWERS-timeItoIpeak,IpeakIconcentrationIandIAUC
pharmaceuticalIalternativeI-ICORRECTIANSWERS-differentIsalt,Iester,IdosageIform,Istrength
therapeuticIsubsitutionI-ICORRECTIANSWERS-limitedItoIfacilitiesIthatIhaveIaIformulary
theIorangeIbookI-ICORRECTIANSWERS-approvedIdrugIproductsIwithItherapeuticIequivalents
NTII-ICORRECTIANSWERS-lessIthanI2IfoldIdifferenceIbetweenILD50IandIED50
lessIthanI2IfoldIdifferenceIbetweenIMTCIandIMEC
variabilityIofIdrugsI-IFDAI-ICORRECTIANSWERS-90-110%
95-105%I(NTI)
RLDI-ICORRECTIANSWERS-referenceIstandard
howIlongIdoesIaIdistributerIhaveItoIfillItheIremainingIquanityIofIaIpartiallyIfilledI222IformI-
ICORRECTIANSWERS-60Idays
whereIshouldItheIpharmacistIrecordIaIcontrolledIshipmentI-ICORRECTIANSWERS-copyI3
whenIdoesIaIsupplierIhaveItoIsendIcopyI2ItoItheIDEAI-ICORRECTIANSWERS-
byItheIcloseIofItheImonthItheIshipmentIwentIoutIorItheI60IdaysIexpires
colorsIofIformI222I-ICORRECTIANSWERS-copyI1Ibrown
copyI2Igreen
QUESTIONS WITH CORRECT
ANSWERS
HowIlongIshouldIRXIbeIkeptI-ICORRECTIANSWERS-5IyearsIFDA,I10IyearsIMMA
importIinformationIprescriptionIlabelI-ICORRECTIANSWERS-
ptIname,IrxIserialInumber,IdrugIname,Istrength,IandIdirections
AIproductIisI________IifIitIdoesInotIhaveIanIexpirationIdateI-ICORRECTIANSWERS-misbranded
WhoIcanIprovideIaIblanketIwaiverIforInon-childIresistantIcontainerI-ICORRECTIANSWERS-
patientI(physicianIcanIonlyIdoIitIbyIRX)
WhenIareIchildIresistantIcontainersInotIusedI-ICORRECTIANSWERS-hospital/healthcareIsettings
AIpharmacyIdispensingItoIaILTCFIrequiresIwhatItypeIofIcontainerI-ICORRECTIANSWERS-
childIresistant
PolicyIforIreversibleIclosuresI-ICORRECTIANSWERS-discouragedIbyICPSC
productsIexemptIfromIchildIclosuresI-ICORRECTIANSWERS-
sublingualInitro,Isublingual/chewableIisosorbideIdinitrate,Imethylprednisone,Ibetamethasone,
PharmaceuticallyIequivalentI-ICORRECTIANSWERS-
sameIingredient,IdosageIform,Iroute,Istrength/concentration
therapeuticallyIequivalentI-ICORRECTIANSWERS-pharmaIequivIandIbioequivalent
, bioequivalentI-ICORRECTIANSWERS-timeItoIpeak,IpeakIconcentrationIandIAUC
pharmaceuticalIalternativeI-ICORRECTIANSWERS-differentIsalt,Iester,IdosageIform,Istrength
therapeuticIsubsitutionI-ICORRECTIANSWERS-limitedItoIfacilitiesIthatIhaveIaIformulary
theIorangeIbookI-ICORRECTIANSWERS-approvedIdrugIproductsIwithItherapeuticIequivalents
NTII-ICORRECTIANSWERS-lessIthanI2IfoldIdifferenceIbetweenILD50IandIED50
lessIthanI2IfoldIdifferenceIbetweenIMTCIandIMEC
variabilityIofIdrugsI-IFDAI-ICORRECTIANSWERS-90-110%
95-105%I(NTI)
RLDI-ICORRECTIANSWERS-referenceIstandard
howIlongIdoesIaIdistributerIhaveItoIfillItheIremainingIquanityIofIaIpartiallyIfilledI222IformI-
ICORRECTIANSWERS-60Idays
whereIshouldItheIpharmacistIrecordIaIcontrolledIshipmentI-ICORRECTIANSWERS-copyI3
whenIdoesIaIsupplierIhaveItoIsendIcopyI2ItoItheIDEAI-ICORRECTIANSWERS-
byItheIcloseIofItheImonthItheIshipmentIwentIoutIorItheI60IdaysIexpires
colorsIofIformI222I-ICORRECTIANSWERS-copyI1Ibrown
copyI2Igreen